Corvus Pharmaceuticals (NASDAQ:CRVS) Now Covered by HC Wainwright

Investment analysts at HC Wainwright initiated coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a note issued to investors on Thursday, MarketBeat reports. The brokerage set a “buy” rating and a $11.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 88.68% from the company’s current price. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q4 2024 earnings at ($0.12) EPS and FY2029 earnings at $0.49 EPS.

A number of other brokerages also recently weighed in on CRVS. StockNews.com downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Oppenheimer increased their target price on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. LADENBURG THALM/SH SH lifted their price target on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Finally, Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Trading Up 7.4 %

NASDAQ CRVS opened at $5.83 on Thursday. Corvus Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $10.00. The stock has a 50-day simple moving average of $7.67 and a 200 day simple moving average of $5.29. The company has a market capitalization of $374.62 million, a PE ratio of -6.27 and a beta of 1.05.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at about $44,000. Nwam LLC acquired a new position in Corvus Pharmaceuticals during the 3rd quarter worth approximately $53,000. XTX Topco Ltd bought a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth approximately $74,000. Virtu Financial LLC acquired a new stake in shares of Corvus Pharmaceuticals in the third quarter valued at approximately $83,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of Corvus Pharmaceuticals in the third quarter valued at approximately $89,000. Institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.